About Us
Chairwoman of the Board, Executive Director: Ms. Theresa Tse
-
- Chairwoman of the Board, Executive Director: Ms. Theresa Tse
- Since 2015, Theresa Tse has served as Chairwoman of the Board of Sino Biopharmaceutical Limited (SBP Group, 1177.HK) and Vice Chairwoman of Chia Tai Pharmaceutical Group. In 2017, she served as the Director of Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ) and Vice Chairwoman of Beijing Tide Pharmaceutical Co., Ltd. Ms. Theresa Tse holds a Bachelor of Science Degree in Economics from the Wharton School of the University of Pennsylvania. She has been listed on Forbes' "Top 100 Businesswomen in China" eight times and was selected for Bloomberg Businessweek's "Bloomberg 50" in 2024.
Since taking office, Ms. Tse has led the company's strategic transformation. By continuously increasing R&D investment, establishing global innovation platforms, and advancing strategic investments and acquisitions, she has accelerated the transformation and upgrading of the Company’s business structure. Under her leadership, SBP Group has continued to strengthen resource integration and global partnerships, establishing multi-level collaborations with multinational pharmaceutical companies including AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Sanofi. The Group has also completed strategic acquisitions of companies including Laekna Therapeutics and Hejia Bio, significantly enhancing its innovation capabilities and global competitiveness.
Adhering to the brand philosophy of "Science for a healthier world", SBP Group focuses on four major areas: oncology, hepatology/cardiometabolism, respiratory/autoimmunity, and surgery/analgesia. The Group continues to accelerate the translation of innovative achievements and expand its global market presence. In recent years, the Company has steadily increased its R&D investment as a percentage of revenue, while its innovative pipeline has entered a period of accelerated value realization. Its innovative medicine business has become a key growth engine driving the Company’s high-quality development.
While pursuing innovation-driven growth, Ms. Tse places great emphasis on corporate social responsibility and sustainable development. She has led SBP Group and its member companies in actively participating in charitable initiatives and fulfilling CP Group’s business philosophy of “Benefit the Country, Benefit the People, Benefiting the Company.” She has also promoted the establishment of an ESG governance framework centered on “CARE” (Cure, Accessible, Relationship, Environmental) while continuously enhancing management practices in areas including carbon neutrality planning, medicine accessibility, employee development, and responsible supply chains.
Under Ms. Tse’s leadership, SBP Group was included as a constituent stock of the Hang Seng Index in 2018 and became a constituent stock of the Hang Seng Stock Connect China Biotech 50 Index in 2020. The Group has been listed among the “Top 50 Global Pharmaceutical Companies” for seven consecutive years, recognized among Forbes's (Asia) “Best Companies in Asia-Pacific” for three consecutive years, and its MSCI ESG Rating has been upgraded to AA. Its core subsidiaries, CTTQ and Beijing Tide Pharmaceutical have been repeatedly recognized among the “Top 100 Pharmaceutical Industrial Enterprises in China.”
*Portrait rights belong to the individual. Unauthorized use is prohibited.
-
Breaking Through in International Multicenter Clinical Mutual Recognition, "R&D Without Borders · SBP Group Sets Sail" International Biopharmaceutical Innovation and Development Forum Held in Shanghai 2026.06
On June 6, the "R&D Without Borders · SBP Group Sets Sail" International Biopharmaceutical Innovation and Development Forum was held at the Chia Tai Tianqing Global R&D Headquarters in Minhang District, Shanghai.View > -
"We Cannot Always Be on the Path of Catching Up": Theresa Tse Decodes the Blue Ocean of Innovation for SBP Group at CICC Healthcare Investment Conference 2026.05
On May 14, the 6th CICC Healthcare Industry Summit 2026 was held in Shanghai. Theresa Tse, Chairwoman of the Board of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), attended and delivered a speech, providing a clear answer for achieving a global breakthrough through a differentiated M&A strategy for local Chinese pharmaceutical companies, combined with a leading advantage across the entire value chain.View > -
Asia Summit on Global Health Opens, Theresa Tse: Pharmaceutical Innovation is a Marathon, Willing to Build an Open Ecosystem with Global Peers 2026.05
On the morning of May 11, the 6th Asia Summit on Global Health (ASGH), co-hosted by the HKSAR Government and the Hong Kong Trade Development Council, opened at the Hong Kong Convention and Exhibition Centre.View > -
SBP Group Releases 2025 Annual Results: Revenue and Net Profit Maintain Double-Digit Growth, Innovative Product Revenue Exceeds RMB 15 Billion 2026.03
On March 26, Sino Biopharmaceutical Limited (SBP Group, 1177.HK) released its 2025 annual results. Driven by the in-depth advancement of its comprehensive innovation and development strategy and the rapid volume growth of innovative products launched intensively over the past three years, the company has delivered impressive results of double-digit growth in both revenue and net profit for four consecutive reporting periods.View > -
Theresa Tse Invited to China Development Forum, Empowering High-Quality Development of the Pharmaceutical Industry Through Open Cooperation 2026.03
On March 22, the China Development Forum 2026 Annual Conference opened in Beijing. Qiang Li, a member of the Standing Committee of the Political Bureau of the CPC Central Committee and Premier of the State Council, attended the opening ceremony and delivered a keynote speech.View > -
SBP Group Reaches Exclusive Licensing Agreement with Sanofi for Rovadicitinib 2026.03
On March 4, Sino Biopharmaceutical Limited (SBP Group, 1177.HK) announced that it has reached an exclusive licensing agreement with Sanofi for Rovadicitinib, a novel, potent, first-in-class (FIC) oral small-molecule JAK/ROCK inhibitor.View > -
Ms. Theresa Tse Named to Forbes China List of Top 100 Outstanding Businesswomen in 2026, Leading the Leapfrog Development of Sino Biopharmaceutical Limited 2026.03
On March 9, the 2026 Forbes China list of Top 100 Outstanding Businesswomen was officially released, and the Chairwoman of the Board of Sino Biopharmaceutical Limited (SBP Group, 1177.HK) was once again included for her profound influence in the field of pharmaceutical innovation.View > -
Bloomberg Interview | Theresa Tse, Chairwoman of the Board of SBP Group: Driving Innovation Through M&A, Accelerating the Implementation of Globalization Strategy 2026.01
On January 14, following the completion of the major transaction of a RMB 1.2 billion full acquisition of Hygieia, Ms. Theresa Tse, Chairwoman of the Board of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), was interviewed by the globally renowned financial media outlet Bloomberg. She elaborated on the strategic significance of this acquisition and answered questions regarding future investment layout, implementation of the globalization strategy, and other topics.View > -
Asian Financial Forum | Theresa Tse: Driving Innovative Achievements with International Potential to the Global Stage 2026.01
From January 26 to 27, the 19th Asian Financial Forum was held in Hong Kong.View > -
.jpg)
Major News! SBP Group Acquires Hygieia for RMB 1.2 Billion, Joins Forces with "Industry Dark Horse" in Small Nucleic Acid to Accelerate Layout in Major Chronic Diseases 2026.01
On January 13, Sino Biopharmaceutical Limited (SBP Group, 1177.HK) announced that it will fully acquire Hangzhou Hygieia Pharmaceuticals Co., Ltd. (hereinafter referred to as "Hygieia"), a domestic innovative drug company in the small interfering RNA (siRNA) field, for a total price of RMB 1.2 billion.View >